早期NT-proBNP升高预测急性缺血性卒中再灌注治疗后恶性水肿与死亡
本研究纳入1039例接受再灌注治疗(静脉溶栓和/或血管内取栓)的急性缺血性卒中患者,检测早期NT-proBNP水平。结果显示Ln(NT-proBNP)与3个月死亡率和恶性脑水肿独立相关,在单纯静脉溶栓和血管内取栓患者中均显著。
要点
- 早期NT-proBNP升高与再灌注治疗后恶性脑水肿和死亡独立相关。
- 单纯静脉溶栓和血管内取栓患者中关联均显著。
- NT-proBNP或可辅助风险分层,需进一步验证。
核心结论
- 早期NT-proBNP水平升高与再灌注治疗后恶性水肿和卒中死亡相关。
研究设计与样本
- 研究纳入1039例急性缺血性卒中患者,检测早期NT-proBNP(静脉溶栓者在阿替普酶输注开始后2小时,血管内取栓者在取栓结束时)。
- 对NT-proBNP进行自然对数转换(Ln(NT-proBNP)),恶性脑水肿采用SITS-MOST标准判定。
主要发现
- 血清NT-proBNP中位数为349 pg/mL(四分位距89-1250 pg/mL)。
- Ln(NT-proBNP)与单纯静脉溶栓患者3个月死亡率独立相关(OR 1.465,95%CI 1.169-1.836,P=0.001)。
- Ln(NT-proBNP)与血管内取栓患者3个月死亡率独立相关(OR 1.563,95%CI 1.139-2.145,P=0.006)。
- Ln(NT-proBNP)与单纯静脉溶栓患者恶性水肿独立相关(OR 1.334,95%CI 1.020-1.745,P=0.036),与血管内取栓患者恶性水肿独立相关(OR 1.455,95%CI 1.057-2.003,P=0.022)。
临床怎么用
- 对于接受再灌注治疗的急性缺血性卒中患者,早期检测NT-proBNP可能有助于识别恶性水肿和死亡高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We aimed to investigate the relationship between early NT-proBNP (N-terminal probrain natriuretic peptide) and all-cause death in patients receiving reperfusion therapy, including intravenous thrombolysis and endovascular thrombectomy (EVT). METHODS: This study included 1039 acute ischemic stroke patients with early NT-proBNP data at 2 hours after the beginning of alteplase infusion for those with intravenous thrombolysis only or immediately at the end of EVT for those with EVT. We performed natural log transformation for NT-proBNP (Ln(NT-proBNP)). Malignant brain edema was ascertained by using the SITS-MOST (Safe Implementation of Thrombolysis in Stroke-Monitoring Study) criteria. RESULTS: Median serum NT-proBNP level was 349 pg/mL (interquartile range, 89-1250 pg/mL). One hundred twenty-one (11.6%) patients died. Malignant edema was observed in 78 (7.5%) patients. Ln(NT-proBNP) was independently associated with 3-month mortality in patients with intravenous thrombolysis only (odds ratio, 1.465 [95% CI, 1.169-1.836]; P=0.001) and in those receiving EVT (odds ratio, 1.563 [95% CI, 1.139-2.145]; P=0.006). The elevation of Ln(NT-proBNP) was also independently associated with malignant edema in patients with intravenous thrombolysis only (odds ratio, 1.334 [95% CI, 1.020-1.745]; P=0.036), and in those with EVT (odds ratio, 1.455 [95% CI, 1.057-2.003]; P=0.022). CONCLUSIONS: An early increase in NT-proBNP levels was related to malignant edema and stroke mortality after reperfusion therapy.
引用
- Zhang X, Yan S, Zhong W, et al. Early NT-ProBNP (N-Terminal Probrain Natriuretic Peptide) Elevation Predicts Malignant Edema and Death After Reperfusion Therapy in Acute Ischemic Stroke Patients. Stroke. 2021. PMID: 33406870. doi:10.1161/STROKEAHA.120.029593
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。